vs
Ares Commercial Real Estate Corp（ACRE）与Protalix BioTherapeutics, Inc.（PLX）财务数据对比。点击上方公司名可切换其他公司
Ares Commercial Real Estate Corp的季度营收约是Protalix BioTherapeutics, Inc.的1.4倍（$13.2M vs $9.1M），Ares Commercial Real Estate Corp净利率更高（-29.2% vs -60.3%，领先31.1%），Ares Commercial Real Estate Corp同比增速更快（-24.5% vs -49.9%），过去两年Protalix BioTherapeutics, Inc.的营收复合增速更高（-6.7% vs -15.9%）
Ares Commercial Real Estate Corp是隶属于阿瑞斯管理集团的专业金融企业，专注于商业地产领域，提供优先抵押贷款、次级债务、优先股投资等各类定制化融资解决方案，主要服务覆盖美国全境的中型商业地产所有者及运营主体。
Protalix BioTherapeutics是一家以色列制药企业，核心产品为植物源酶制剂他利苷酶阿尔法，该产品已获美国食品药品监督管理局批准，用于治疗戈谢病，专注于开发创新生物技术药物服务患者需求。
ACRE vs PLX — 直观对比
营收规模更大
ACRE
是对方的1.4倍
$9.1M
营收增速更快
ACRE
高出25.4%
-49.9%
净利率更高
ACRE
高出31.1%
-60.3%
两年增速更快
PLX
近两年复合增速
-15.9%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $13.2M | $9.1M |
| 净利润 | $-3.9M | $-5.5M |
| 毛利率 | — | 49.4% |
| 营业利润率 | -29.2% | -51.1% |
| 净利率 | -29.2% | -60.3% |
| 营收同比 | -24.5% | -49.9% |
| 净利润同比 | 63.8% | -184.8% |
| 每股收益（稀释后） | — | $-0.06 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ACREPLX
| Q4 25 | $13.2M | $9.1M | ||
| Q3 25 | $14.1M | $17.9M | ||
| Q2 25 | $12.6M | $15.7M | ||
| Q1 25 | $14.9M | $10.1M | ||
| Q4 24 | $17.5M | $18.2M | ||
| Q3 24 | $16.7M | $18.0M | ||
| Q2 24 | $16.8M | $13.5M | ||
| Q1 24 | $18.7M | — |
净利润ACREPLX
| Q4 25 | $-3.9M | $-5.5M | ||
| Q3 25 | $4.7M | $2.4M | ||
| Q2 25 | $-11.0M | $164.0K | ||
| Q1 25 | $9.3M | $-3.6M | ||
| Q4 24 | $-10.7M | $6.5M | ||
| Q3 24 | $-5.9M | $3.2M | ||
| Q2 24 | $-6.1M | $-2.2M | ||
| Q1 24 | $-12.3M | — |
毛利率ACREPLX
| Q4 25 | — | 49.4% | ||
| Q3 25 | — | 53.4% | ||
| Q2 25 | — | 62.5% | ||
| Q1 25 | — | 19.1% | ||
| Q4 24 | — | 78.7% | ||
| Q3 24 | — | 53.4% | ||
| Q2 24 | — | 29.8% | ||
| Q1 24 | — | — |
营业利润率ACREPLX
| Q4 25 | -29.2% | -51.1% | ||
| Q3 25 | 33.0% | 11.9% | ||
| Q2 25 | -87.8% | 7.5% | ||
| Q1 25 | 64.4% | -41.0% | ||
| Q4 24 | -61.0% | 39.6% | ||
| Q3 24 | -35.3% | 22.2% | ||
| Q2 24 | -36.5% | -18.0% | ||
| Q1 24 | -65.9% | — |
净利率ACREPLX
| Q4 25 | -29.2% | -60.3% | ||
| Q3 25 | 33.0% | 13.2% | ||
| Q2 25 | -87.8% | 1.0% | ||
| Q1 25 | 62.5% | -35.8% | ||
| Q4 24 | -60.9% | 35.6% | ||
| Q3 24 | -35.3% | 18.0% | ||
| Q2 24 | -36.5% | -16.4% | ||
| Q1 24 | -65.9% | — |
每股收益（稀释后）ACREPLX
| Q4 25 | — | $-0.06 | ||
| Q3 25 | — | $0.03 | ||
| Q2 25 | — | $0.00 | ||
| Q1 25 | — | $-0.05 | ||
| Q4 24 | — | $0.10 | ||
| Q3 24 | — | $0.03 | ||
| Q2 24 | — | $-0.03 | ||
| Q1 24 | — | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $29.3M | $14.7M |
| 总债务越低越好 | $948.2M | — |
| 股东权益账面价值 | $509.6M | $48.2M |
| 总资产 | $1.6B | $82.3M |
| 负债/权益比越低杠杆越低 | 1.86× | — |
8季度趋势，按日历期对齐
现金及短期投资ACREPLX
| Q4 25 | $29.3M | $14.7M | ||
| Q3 25 | $84.9M | $13.6M | ||
| Q2 25 | $90.0M | $17.9M | ||
| Q1 25 | $125.5M | $19.5M | ||
| Q4 24 | $63.8M | $19.8M | ||
| Q3 24 | $68.9M | $27.4M | ||
| Q2 24 | $70.6M | $23.4M | ||
| Q1 24 | $99.5M | — |
总债务ACREPLX
| Q4 25 | $948.2M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $718.5M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益ACREPLX
| Q4 25 | $509.6M | $48.2M | ||
| Q3 25 | $521.0M | $52.9M | ||
| Q2 25 | $523.7M | $49.9M | ||
| Q1 25 | $542.1M | $45.2M | ||
| Q4 24 | $540.1M | $43.2M | ||
| Q3 24 | $563.8M | $32.4M | ||
| Q2 24 | $582.3M | $28.6M | ||
| Q1 24 | $601.1M | — |
总资产ACREPLX
| Q4 25 | $1.6B | $82.3M | ||
| Q3 25 | $1.4B | $82.3M | ||
| Q2 25 | $1.4B | $78.5M | ||
| Q1 25 | $1.5B | $73.9M | ||
| Q4 24 | $1.8B | $73.4M | ||
| Q3 24 | $1.9B | $61.6M | ||
| Q2 24 | $2.1B | $91.5M | ||
| Q1 24 | $2.1B | — |
负债/权益比ACREPLX
| Q4 25 | 1.86× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 1.33× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $21.4M | $2.0M |
| 自由现金流经营现金流 - 资本支出 | — | $1.6M |
| 自由现金流率自由现金流/营收 | — | 17.8% |
| 资本支出强度资本支出/营收 | — | 4.4% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-13.6M |
8季度趋势，按日历期对齐
经营现金流ACREPLX
| Q4 25 | $21.4M | $2.0M | ||
| Q3 25 | $3.8M | $-3.7M | ||
| Q2 25 | $4.9M | $-5.2M | ||
| Q1 25 | $8.0M | $-5.1M | ||
| Q4 24 | $35.5M | $4.0M | ||
| Q3 24 | $8.4M | $4.1M | ||
| Q2 24 | $8.7M | $-3.6M | ||
| Q1 24 | $11.4M | — |
自由现金流ACREPLX
| Q4 25 | — | $1.6M | ||
| Q3 25 | — | $-4.2M | ||
| Q2 25 | — | $-5.7M | ||
| Q1 25 | — | $-5.4M | ||
| Q4 24 | — | $3.6M | ||
| Q3 24 | — | $4.0M | ||
| Q2 24 | — | $-3.8M | ||
| Q1 24 | — | — |
自由现金流率ACREPLX
| Q4 25 | — | 17.8% | ||
| Q3 25 | — | -23.7% | ||
| Q2 25 | — | -36.2% | ||
| Q1 25 | — | -53.0% | ||
| Q4 24 | — | 19.6% | ||
| Q3 24 | — | 22.4% | ||
| Q2 24 | — | -28.1% | ||
| Q1 24 | — | — |
资本支出强度ACREPLX
| Q4 25 | — | 4.4% | ||
| Q3 25 | — | 2.8% | ||
| Q2 25 | — | 2.8% | ||
| Q1 25 | — | 3.0% | ||
| Q4 24 | — | 2.3% | ||
| Q3 24 | — | 0.5% | ||
| Q2 24 | — | 1.3% | ||
| Q1 24 | — | — |
现金转化率ACREPLX
| Q4 25 | — | — | ||
| Q3 25 | 0.82× | -1.58× | ||
| Q2 25 | — | -31.91× | ||
| Q1 25 | 0.86× | — | ||
| Q4 24 | — | 0.61× | ||
| Q3 24 | — | 1.27× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ACRE
暂无分部数据
PLX
| Products | $8.7M | 95% |
| Other | $428.0K | 5% |
